15:30:30 EDT Tue 28 Mar 2017
Enter Symbol
or Name
USA
CA



Z:SNY - SANOFI - http://www.sanofi-aventis.com15:30:30 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNY - Z0.545.36 · 45.370.745.3635-0.01650.02,033.886,5479,45445.235  45.95  45.1845.49  36.8115:15:1813:5015 min RT 2¢

Recent Trades - Last 10 of 9454
Time ETExPriceChangeVolume
15:15:18Z45.3635-0.0165215
15:15:08Z45.37-0.01100
15:15:03Z45.37-0.01100
15:15:02Z45.36-0.02100
15:15:00Z45.37-0.01100
15:15:00Z45.37-0.0116
15:15:00Z45.37-0.01160
15:15:00Z45.37-0.01100
15:15:00Z45.37-0.01100
15:15:00Z45.37-0.01100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2017-03-28 13:50U:SNYNews ReleaseRegeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT ® (dupilumab) Approval
2017-03-28 11:40U:SNYNews ReleaseRegeneron and Sanofi Announce FDA Approval of DUPIXENT ® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
2017-03-28 11:40U:SNYNews ReleaseSanofi and Regeneron Announce FDA Approval of Dupixent ® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
2017-03-25 06:00U:SNYNews ReleaseKeller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin
2017-03-22 07:30U:SNYNews ReleaseSanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education
2017-03-21 07:30U:SNYNews ReleaseSanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S.
2017-03-14 05:46U:SNYNews ReleaseSanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes
2017-03-07 08:00U:SNYNews ReleaseRegeneron and Sanofi to Present New Phase 3 Praluent ® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions
2017-03-04 10:30U:SNYNews ReleaseRegeneron and Sanofi Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DUPIXENT ® (dupilumab) in Moderate-to-Severe Atopic Dermatitis